Non-Muscle Invasive Bladder Neoplasms: all 273 studies

Page 1 of 3. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.

• Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)Not yet recruitingNCT07893509
• Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder CarcinomaNot yet recruitingNCT07874347Phase 1/2
• The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder CancerNot yet recruitingNCT07873333Not applicable
• Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial Bladder TumorsRecruitingNCT07860398Not applicable
• Feasibility of HISA During TURBT for NMIBCNot yet recruitingNCT07817173Not applicable
• Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBTNot yet recruitingNCT07808216Phase 2
• A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder CancerRecruitingNCT07804056Phase 3
• Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder CancerNot yet recruitingNCT07800507Phase 1/2
• Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion: Construction and Preliminary ApplicationNot yet recruitingNCT07781956Not applicable
• A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC).Not yet recruitingNCT07777848Phase 2
• Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)RecruitingNCT07763197
• Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC.Not yet recruitingNCT07758881Not applicable
• Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBCRecruitingNCT07749924Not applicable
• Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder CancerRecruitingNCT07747740Phase 2
• LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the BladderRecruitingNCT07728474Not applicable
• A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBCRecruitingNCT07725796Phase 1
• Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder CancerRecruitingNCT07673016
• Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder CancerRecruitingNCT07646145Phase 2
• Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?RecruitingNCT07625527Phase 2
• Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer StagingRecruitingNCT07602010
• Tumor Budding and T1 Substaging in Urothelial Bladder CancerNot yet recruitingNCT07529639
• Early vs Delayed Intravesical Blad-Care During BCG TherapyRecruitingNCT07495072Not applicable
• Effects of Microbiological and Immunological Factors on the Lower Urinary TractRecruitingNCT07494864
• Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerRecruitingNCT07480356Phase 3
• Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder CancerRecruitingNCT07474519Phase 4
• A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder CancerNot yet recruitingNCT07464145Phase 3
• The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.Not yet recruitingNCT07445308Phase 1/2
• A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCRecruitingNCT07424287Phase 3
• Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention StudyRecruitingNCT07339761Not applicable
• Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBCRecruitingNCT07322263Phase 2
• A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United StatesRecruitingNCT07309445
• Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinRecruitingNCT07283835Phase 2
• A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.Not yet recruitingNCT07268339Phase 3
• Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)Not yet recruitingNCT07260162Phase 1
• Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC PatientsNot yet recruitingNCT07231809Not applicable
• Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2RecruitingNCT07225127
• DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBCRecruitingNCT07207824Phase 3
• A Study to Learn About the Study Medicine PF-08052667 in People With Bladder CancerRecruitingNCT07206225Phase 1
• Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized TrialNot yet recruitingNCT07198451Phase 2/3
• Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 StudyNot yet recruitingNCT07189793Phase 2
• Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder CancerRecruitingNCT07187063Not applicable
• Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyRecruitingNCT07144319
• The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder CancerRecruitingNCT07130578
• A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder CancerRecruitingNCT07122414Phase 1/2
• RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC PatientsNot yet recruitingNCT07100184Phase 2
• A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.Not yet recruitingNCT07064863Phase 1/2
• Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing TherapyNot yet recruitingNCT07053748
• A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth SequencingRecruitingNCT07036731Not applicable
• Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG TherapyRecruitingNCT07000084Phase 3
• Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerRecruitingNCT06995677Phase 2
• Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 StudyRecruitingNCT06990061Not applicable
• Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG TherapyRecruitingNCT06972615Phase 2
• A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)RecruitingNCT06929286Phase 3
• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerRecruitingNCT06919965Phase 3
• Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder CancerRecruitingNCT06889623Not applicable
• A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)RecruitingNCT06833073Phase 2
• Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNot yet recruitingNCT06829823Phase 2
• ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder CancerAvailableNCT06810141
• ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCGRecruitingNCT06800963Phase 1/2
• Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder CancerRecruitingNCT06781879Phase 4
• A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder CancerRecruitingNCT06735287Not applicable
• A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder CancerRecruitingNCT06733363Phase 2
• Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder CancerRecruitingNCT06732531Phase 1/2
• In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE TrialRecruitingNCT06704191Phase 1/2
• Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC PatientsRecruitingNCT06696794Phase 3
• T-Control® Safety for Cytostatics ManagementNot yet recruitingNCT06678633Not applicable
• A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBCRecruitingNCT06663137Phase 2
• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)RecruitingNCT06637423Phase 1/2
• A Clinical Trial Aimed At Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder CancerRecruitingNCT06632964Phase 1
• A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.Not yet recruitingNCT06630871Phase 2
• SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBtNot yet recruitingNCT06588179Phase 1/2
• Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)RecruitingNCT06551233Phase 1
• A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder CancerRecruitingNCT06503614Phase 2
• An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGAvailableNCT06443944
• Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder CancerRecruitingNCT06441110Phase 3
• To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2RecruitingNCT06378242Phase 1/2
• Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer PatientsNot yet recruitingNCT06374914
• A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) TherapyRecruitingNCT06351904Phase 1
• HIVEC in Patients With Non-Muscle-Invasive Bladder CancerNot yet recruitingNCT06327932Phase 3
• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerRecruitingNCT06319820Phase 3
• The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral ResectionRecruitingNCT06287541Not applicable
• The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer PatientsRecruitingNCT06245759
• A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder CancerRecruitingNCT06245603Not applicable
• Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)RecruitingNCT06241755Phase 3
• Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived OrganoidsNot yet recruitingNCT06227065Phase 2
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBCRecruitingNCT06186414Phase 1
• PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder CancerRecruitingNCT06173349Phase 1
• Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.RecruitingNCT06167356
• A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)RecruitingNCT06108492Phase 1
• RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder CancerNot yet recruitingNCT05996952Phase 2
• Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder CancerRecruitingNCT05975151Phase 2
• Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)RecruitingNCT05962541Phase 4
• RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 ExpressionRecruitingNCT05957757Phase 2
• Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerRecruitingNCT05951179Phase 2
• Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)RecruitingNCT05825950
• Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer SurveillanceRecruitingNCT05796375Phase 2
• Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)RecruitingNCT05790850Not applicable
• Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer PatientsRecruitingNCT05739968Not applicable
• A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder CancerRecruitingNCT05710848Phase 1/2
• Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCGRecruitingNCT05672615

← Non-Muscle Invasive Bladder Neoplasms overview